Introduction
============

Volatile substance abuse (VSA) is an especially important problem, because inhalants are daily-used substances, the age of onset of VSA is early, and acts as a gateway toward abuse of more dangerous substances. Inhalants are thought to be the first substances which children abuse; especially because inhalants are cheap, easily accessible, legally freely sold, in a packaging suitable for use, and have a quick impact \[[@B1],[@B2]\]. Inhalants are volatile hydrocarbons such as toluene, n-hexane, methyl butyl ketone, trichlorethylene, trichlorethane, dichloro methane, gasoline and butane.

In Turkey, the most widely used inhalants are paint thinners, and glues \[[@B3]\]. Because of the highly lipophilic character of inhalants, their use exerts harmful effects on various systems, and primarily on the nervous system. The most important acute effect of volatiles is sudden death, which is thought to develop as a result of vagal inhibition, anoxia, respiratory failure, and cardiac arrhythmia \[[@B3],[@B4]\]. Long-term low-dose volatile substance abuse may cause nervous system damage, such as muscle weakness, tremor, peripheral neuropathy, cerebellar dysfunction, chronic encephalopathy, and dementia \[[@B5]-[@B8]\]. In addition, there are also non-neurologic complications such as congestive heart failure, distal renal tubular acidosis, metabolic acidosis with high anion gap, Fanconi syndrome, nephrolithiasis, glomerulonephritis, Goodpasture\'s syndrome, toxic hepatitis, reversible hepatorenal failure, leukemia, and aplastic anemia \[[@B8]\].

VSA is a problem which is gaining importance in children and young adults of developed nations, along with developing nations. A research conducted by the United Nations Office on Drugs and Crime (UNODC) found the age of onset to be 11 for inhalants, 16 for cannabis, and 17 for ecstasy \[[@B9]\]. Therefore, it is necessary to investigate the effects of abuse of inhalants on health, and to inform and educate these children, their families, and society in general. Inhalants are widely abused and have many known adverse effects; but there are few published clinical research studies in the literature to date investigating the long-term pulmonary toxicity of volatile inhalants. In this study, we aimed to determine the physiologic effects of inhaling solvents on the respiratory functions of the adolescent inhalant abusers.

Materials and methods
=====================

This is a case-control study, conducted between November 2006 and November 2007, as a joint collaboration between Ege University Faculty of Medicine, Department of Pediatrics, Division of Pulmonology and Allergy, and Ege University Child and Adolescent Addiction Investigation and Practice Center (EGEBAM). The approval of the Institutional Ethics Committee of Ege University Faculty of Medicine was obtained before the initiation of study.

Study group
-----------

The subject group of this study were the individuals undergoing inpatient treatment at the Ege University Child and Adolescent Addiction Investigation and Practice Center (EGEBAM). Criteria for inclusion in the study were that subjects: i) met the diagnostic criteria of DSM-IV-TR inhalant-related disorders; and ii) were able to cooperate in the study, by responding to questions, and undergoing the necessary examinations. Exclusion criteria were: i) a history of chronic systemic illness, or assuming a pharmaceutical drug for this type of illness, in the period before the development of sustance abuse; ii) presence of a psychological disorder, at a level which would not allow participating in, or continuing with the study.

A total of 31 volatile substance abusers were admitted to the study. The age range of the patient group was 13-21 years. The control group comprised 19 subjects, selected from adolescents who had no health problem and who did not abuse any substance. All of the subjects who met the criteria for inclusion in the study, and their parents, were informed both verbally and in writing. After this, a questionnaire was administered that probed their sociodemographic characteristics, and respiratory system complaints. Detailed physical examination of all the subjects was performed. The severity of inhalant abuse was assessed, by a psychiatrist experienced in substance abuse disorders, by administering YUKUD (Yeniden Adolescent Inhalant Use Severity Scale), which consists of 18 questions. Subjects underwent a pulmonary function test, ventilation-perfusion scintigraphy, and high-resolution computerized tomography (HRCT).

Statistical evaluation
----------------------

Statistical analyses were performed using \"SPSS (Statistical Package for Social Sciences) 15.0 for Windows\" software. The results were evaluated with a 95% confidence interval, and p \< 0.05 was accepted as statistically significant.

Results
=======

Sociodemographic characteristics
--------------------------------

A total of 31 subjects took part in the study. All subjects were males, with an average age of 17.9 ± 1.5 (13.3-20.1) years. Applicants who were resident within Izmir were 81.1%, those coming from outside of Izmir were 12.9%. The mothers of 96.8%, and fathers of 93.5%, were alive; mothers\' cigarette smoking rate was 58.1%, while fathers\' was 41.9%, and fathers\' rate of consuming both alcohol and cigarettes was 41.9%. Only 16.2% of the fathers were not using a substance. The percentage of subjects living at home with their family was 96.8%. The rate of running away from home without informing their family was 90.3%. The length of time these subjects had lived on the street varied between 1 to 45 days, with a mean of 8.6 ± 12.4 days. Upon investigating their educational status, 90.3% of the subjects were found to be not attending school. The years of education that the subjects had had were between 1 and 13, with a mean of 7.8 ± 2.8 years. Until the time of admission to EGEBAM, 93.5% of the subjects had worked in an occupation related to some volatile substance. The family income of 16% of subjects was 0-400 euros/month, of 67% was 400-700 euros/month, and of 16.1% was ≥ 700 euros/month.

In the study group, 5 subjects (16.1%) reported having had a suicide attempt. There were 26 (64.5%) subjects with a criminal record, and 6 of these (19.3%) had done time in prison because of substance abuse. 74.2% of the subjects reported previously having gotten medical help because of substance abuse. Occurrence of inpatient treatment because of substance addiction was between 1 and 6 times, with a mean of 1.9 ± 1.4. Except for glue (trademark: Bally) and paint thinner, no other inhalant abuse was found. The rate of Bally abuse was 80.6%, paint thinner 6.5%, and those who abused both were 12.9% (Table [1](#T1){ref-type="table"}).

###### 

The Distribution of Inhalants Being Abused Among the Study Subjects

  Volatile Substance Abuse   n (%)
  -------------------------- ------------
  Paınt thinner              2 (6.5%)
  Glue (trademark, Bally)    25 (80.6%)
  Thinner + Bally            4 (12.9%)

Cigarette smoke was the substance most used along with inhalants. After cigarettes, followed hashish, ecstasy, benzodiazepine, alcohol and cocaine addictions. Cigarette abuse rate was 3.2%, addiction rate 87.1%; hashish abuse rate 29%, addiction rate 54.8%; ecstasy abuse rate 25.8%, addiction rate 29%; benzodiazepine abuse rate 19.4%, addiction rate 19.4%; alcohol abuse rate 51.6%, addiction rate 16.1%, cocaine abuse rate 9.7%, and addiction rate 3.2% (Table [2](#T2){ref-type="table"}). The mean age of onset of VSA was 14.2 ± 2.2 (9-18) years. The age of onset of abuse of the other substances was: 11.8 ± 2.7 (7-16) years for cigarettes, 14.2 ± 2.0 (10-18) years for alcohol, 14.5 ± 2.1 (10-19) years for hashish, 14.7 ± 1.6 (12-17) years for benzodiazepine, 15.0 ± 2.6 (12-18) years for cocaine, and 15.2 ± 1.4 (12-17) years for ecstasy.

###### 

The Age of Onset, and The Rates of Abuse and Addiction, for each Substance

  Substance name    Age of onset (years) Mean ± SD   Abuse n (%)   Addiction n (%)
  ----------------- -------------------------------- ------------- -----------------
  Cigarette smoke   11.85 ± 2.69                     1 (3.2%)      27 (87.1%)
  Inhalant          14.16 ± 2.16                     0             31 (100%)
  Alcohol           14.23 ± 1.97                     16 (51.6%)    5 (16.1%)
  Hashish           14.46 ± 2.06                     9 (29.0%)     17 (54.8%)
  Benzodiazepine    14.75 ± 1.65                     6 (19.4%)     6 (19.4%)
  Cocaine           15.0 ± 2.58                      3 (9.7%)      1 (3.2%)
  Ecstasy           15.17 ± 1.42                     8 (25.8%)     9 (29.0%)

The duration of VSA varied between 1 and 9.2 years, with a mean of 3.7 ± 1.7 years. In terms of the duration of abuse, and the amount of substance abused daily, the subjects with an abuse history of 1-2 years were daily abusing a mean of 4.0 ± 1.4 tubes of inhalants, those with 2-3 years were abusing a mean of 4.1 ± 6.8 tubes, those with 3-4 years were abusing a mean of 5.6 ± 2.3 tubes, those with 4-5 years were abusing a mean of 5.7 ± 4.0 tubes, and those with 5 years were abusing 6.1 ± 5.6 tubes.

Evaluation with Yeniden Inhalant Abuse Severity Scale (YUKUD)
-------------------------------------------------------------

YUKUD scale points ranged between 10 and 50, with a mean of 31.0 ± 9.7. Although YUKUD scale points had a weak negative correlation with the age of onset of VSA (as YUKUD scale points increase, age of onset decreases), this was not statistically significant (p \> 0.05). There was no significant relationship between the duration of attending school, the length of time of living on the streets, and the YUKUD scale points (p \> 0.05). Although the YUKUD scale points of those whose mothers smoked cigarettes were found to be higher than for those with non-smoker mothers, that was not a statistically-significant difference (p \> 0.05). Father\'s substance/use status was not significantly related to the YUKUD scale points (p \> 0.05). Although the YUKUD scale points of the subjects who had run away from home were higher than for those who had not run away, that was not statistically significant (p \> 0.05). Also no significant difference was detected in YUKUD scale points for subjects with respect to having suicide attempts or having a criminal record (p \> 0.05).

Respiratory system findings
---------------------------

As shown in Table [3](#T3){ref-type="table"}, the most frequent symptom among the subjects was nasal congestion (45.2%). Following this was: sputum (38.7%), exercise intolerance (32.3%), cough (22.6%), chest pain (16.1%), shortness of breath (9.7%), tachypnea (9.7%), wheezing (6.4%), sneezing (6.4%), and runny nose (6.4%). No symptoms were present amongst the control group, as this group was selected from adolescents without health problems.

###### 

Distribution of Respiratory-Related Complaints Amongst Group (N = 31) of Volatile Substance Abusers

                         N    \%
  ---------------------- ---- -------
  Nasal congestion       14   45.16
  Sputum                 12   38.71
  Exercise intolerance   10   32.26
  Coughing               7    22.58
  Chest pain             5    16.13
  Shortness of breath    3    9.68
  Tachypnea              3    9.68
  Wheezing               2    6.45
  Sneezing               2    6.45
  Runny nose             2    6.45

Pulmonary function tests
------------------------

The groups\' age, weight, and height distributions were not statistically significantly different (p \> 0.05) (Table [4](#T4){ref-type="table"}). The mean FEV~1~value was 3.8 ± 0.6 L in the patient group, while 4.2 ± 0.6 L in the control group, and there was a statistically significant difference between them (p \< 0.05). Calculated as a percentage of the predicted value, the mean FEV~1~of the patient group was 97.7 ± 13.8%, while the control group\'s was 103.4 ± 10.7%, and there was no statistically significant difference between them (p \> 0.05).

###### 

Demographic Characteristics of the Groups

                Study group (n = 31) Mean ± SD   Control group (n = 13) Mean ± SD   p^•^
  ------------- -------------------------------- ---------------------------------- -------
  Age (years)   17.94 ± 1.52                     18.78 ± 0.64                       0.066
  Weight (kg)   67.88 ± 14.16                    64.61 ± 8.54                       0.455
  Height (cm)   173.61 ± 8.92                    176.30 ± 4.95                      0.315

•: Student\'s t-test.

The mean FVC values were 3.90 ± 0.62 L in the patient group compared to 4.3 ± 0.7 L in the control group, the difference between the two groups being statistically significant (p \< 0.05). Calculated as a percentage of the predicted value, the mean FVC was 84.0 ± 11.7% in the patient group vs. 88.7 ± 10.9% in the control group, and there was no statistical significance between the two (p \> 0.05). The mean FEV~1~/FVC ratio was 97.1 ± 4.7 in the study group vs. 97.6 ± 3.3 in the control group. Calculated as a percentage of the predicted value, the mean FEV~1~/FVC was 117.0 ± 5.5% in the patient group vs. 117.4 ± 4.5% in the control group. None of the numerical or percentage values showed a significant difference (p \> 0.05). The average peak expiratory flow (PEF) value, was 6.85 ± 1.08 L/sec in the patient group, compared to 9.5 ± 0.8 L/sec in the control group. Calculated as a percentage of the predicted value, the average PEF was 80.4 ± 17.0% in the patient group vs. 110.2 ± 17.9% in the control group. Both numerical and percentage values were found to be lower in the study group, with a high level of statistical significance (p \< 0.01). The average mean expiratory flow (MEF)~25-75~value was 4.9 ± 1.2 L/sec in the study group compared to 6.3 ± 1.2 L/sec in the control group. Calculated as a percentage of the predicted value, the average MEF~25-75~was 114.6 ± 22.9% in the study group, and 138.9 ± 32.1% in the control group. Both numerical and percentage values were found to be lower in the study group, with a high level of statistical significance (p \< 0.01) (Table [5](#T5){ref-type="table"}).

###### 

Evaluating the pulmonary function tests for the study and control groups

                      Study group (n = 29) Mean ± SD   Control group (n = 13) Mean ± SD   P•
  ------------------- -------------------------------- ---------------------------------- -----------
  FEV~1~(L)           3.78 ± 0.59                      4.23 ± 0.59                        0.029\*
  FEV~1~(%)           97.75 ± 13.85                    103.38 ± 10.75                     0.202
  FVC (L)             3.90 ± 0.62                      4.35 ± 0.71                        0.046\*
  FVC (%)             84.03 ± 11.66                    88.69 ± 10.88                      0.229
  PEF (L/secec)       6.85 ± 1.08                      9.54 ± 0.85                        0.001\*\*
  PEF (%)             80.44 ± 16.97                    110.23 ± 17.88                     0.001\*\*
  FEV~1~/FVC          97.10 ± 4.75                     97.61 ± 3.30                       0.727
  FEV~1~/FVC (%)      117.00 ± 5.55                    117.37 ± 4.53                      0.866
  MEF~25-75~(L/sec)   4.94 ± 1.22                      6.35 ± 1.21                        0.001\*\*
  MEF~25-75~(%)       114.65 ± 22.95                   138.92 ± 32.15                     0.008\*\*

•: Student\'s t-test.

\*p \< 0.05.

\*\*p \< 0.01.

Twelve (41.4%) subjects in the study group and 2 (15.4%) subjects in the control group had a reduction of 20% or more in FVC levels which was not statistically significant (p \> 0.05). There was no statistically significant relationship (p \> 0.05) between a reduction of ≥ 20% in FVC, and the age of onset, nor duration of VSA, nor total amount of abused substances. There was no statistically significant relationship between pulmonary system complaints and a reduction of ≥ 20% FVC (Table [6](#T6){ref-type="table"}).

###### 

Comparing the reduction in FVC with the pulmonary system complaints in the study group

                             **FVC**≤ **80% (n = 12)**   FVC \> 80% (n = 17)   p^•^          
  -------------------------- --------------------------- --------------------- ------ ------ -------
  **Coughing**               2                           16.7                  4      23.5   1.000
  **Shortness of breath**    3                           25.0                  0      0      0.060
  **Tachypnea**              0                           0                     2      11.8   0.498
  **Wheezing**               0                           0                     1      5.9    1.000
  **Chest pain**             2                           16.7                  2      11.8   0.706
  **Sputum**                 4                           33.3                  6      35.3   0.913
  **Exercise intolerance**   5                           41.7                  4      23.5   0.298
  **Sneezing**               0                           0                     2      11.8   0.498
  **Runny nose**             0                           0                     2      11.8   0.498
  **Nasal congestion**       5                           41.7                  8      47.1   0.774

•: Fisher\'s Exact test, where Chi-Square test would be necessary.

The study group was divided into two subgroups, according to their predicted FVC values being below (group 1) vs. above (group 2) 80%. The HRCT findings of the two subgroups showed no statistically significant difference in the rates of small airways disease, nor subpleural nodules (p \> 0.05); but centrilobular nodule and atelectasis rates were significantly higher in the first group (p \< 0.05). There was statistically a highly significant difference (p \< 0.01) between having an abnormal finding in HRCT and having a reduction of ≥ 20% in FVC. Comparing the scintigraphy findings, there was no significant difference concerning perfusion or ventilation disorders (p \> 0.05) (Table [7](#T7){ref-type="table"}).

###### 

Comparing the reduction in FVC, with HRCT and Scintigraphy Findings

                          FCV                      
  ----------------------- ----------- ------------ -----------
  **HRCT**                                         
  Small airways disease   0           2 (13.3%)    0.280
  Subpleural nodule       4 (50.0%)   2 (20.0%)    0.136
  Centrilobular nodule    2(25.0%)    0            0.043\*
  Atelectasis             2 (25.0%)   0            0.043\*
  Normal                  1 (12.5%)   11 (73.3%)   0.009\*\*
  **Scintigraphy**                                 
  Perfusion disorder      3 (33.3%)   4 (28.6%)    1.000
  Ventilation disorder    1 (11.1%)   3 (25.0%)    0.603

*Definition of abbreviations:*FVC, forced vital capacity; HRCT, high resolution computerized tomography.

•: Chi-square test.

\*p \< 0.05.

\*\*p \< 0.01.

Discussion
==========

A \"substance\" is any chemical which is consumable by various means, and influences sensations, perceptions, cognition, or other brain functions with a likelihood of abuse and addiction. \"Substance abuse\" is the recurring use of a substance within a year, which may cause probable social and/or legal problems or physical risk. \"Substance addiction\" is a broad concept of addiction, which reflects the substance having taken a central role in the per-son\'s life, the individual\'s having lost the control over his/her own substance use, and the existence of substance-related physical and psychological problems \[[@B10]\]. Both in Turkey and in the rest of the world, the rates of use of stimulants and sedatives are increasing fast, and the age of onset of VSA is becoming terrifyingly younger. A long-term use of inhalants is known to have harmful effects on many systems, and primarily on the central nervous system. But the literature on the effects on the respiratory system has been limited to a few case reports. In this study, all of the subjects were males with an age range of 13-21 years. This selection was because of the policy of the Ege University Child and Adolescent Addiction Investigation and Practice Center (EGEBAM), that admits only males for inpatient treatment. Investigating the literature also points to males as the more likely to abuse volatile substances \[[@B11],[@B12]\]. EGEBAM started its service in September 2003. Listing the applications to the EGEBAM outpatient service between September 2003 and September 2005, 88.5% of the subjects are found to be males \[[@B13]\].

In Turkey, the widely used volatile substances are paint thinner and glue \[[@B3]\]. Glues contain less toluene than paint thinner, and the abusers report that glue gives more euphoria and hallucinogenic effects, while paint thinner has more sedative and anesthetic effects \[[@B14]\]. In conducted studies, it was found that those who live on the streets prefer paint thinner, while those who live with their family prefer glue \[[@B15],[@B16]\]. This situation may be explained by the different motivation behind the abuse: leisurely pursuit in the case of those who live with their family, while for those who live on the streets the purpose is to stay alive, enduring the cold and danger of the streets, and to lessen the pain of hunger. In this study, the volatile substances which were reported to be abused were only Bally and thinner, Bally abuse rate being 80.6%, thinner 6.5%, and their being used together 12.9%. This marked difference between Bally and thinner usage might be due to the fact that almost all of the subjects were living with their families.

Vega et al. \[[@B11]\] have stated that, in the development of volatile substance addiction, a history of substance abuse in the family and parents\' smoking cigarettes have an important influence. Volatile substance abusers have quite high rates of substance use in their family. In our study there were no substances used in the subjects\' families except for mothers smoking cigarettes and fathers both smoking cigarettes and consuming alcohol. Alcohol consumption rate was 41.9%, while cigarette smoking rate was 58.1% for mothers, and 83.8% for fathers. Only 16.2% of the fathers were not using any substances.

In the case histories of inhalant abusers, a characteristic that is reported in the literature is trouble in their education, such as truancy, failure in school, and/or dropping out without completing their education \[[@B17],[@B18]\]. In a study by Ögel et al. \[[@B19]\], 86.2% of the subjects reported having dropped out of school, and the average length of education was 7.3 years. In a study conducted by Altenkirch and Kinderman \[[@B20]\], 38% of the volatile substance abusers had attendance to a lower grade, and 90% dropped out of school, without completing their 9 year education toward a diploma. In our study, investigating educational status, 90.3% of the subjects were found to be not attending school. The years of education completed by the subjects varied between 1 and 13, similar to the rates reported in the literature, and the average length of education was 7.80 ± 2.79 years.

Shoemakers (production or repair), furniture producers, printers, coiffeurs, painters, personnel of gas-oil stations, car/motorcycle/bicycle repairers, dry-cleaners, those working in petroleum refineries and related industries, personnel of factories using or producing inhalant-solvents, personnel of drug factories, and personnel working in medical fields constitute the increased-risk groups for volatile substance addiction and abuse \[[@B21]\]. A comprehensive study conducted in Mexico by Conyer et al. \[[@B22]\] found male gender, low socio-economic status, and work conditions as the primary risk factors toward VSA. Likewise, in our study, 93.5% of the subjects had previously worked in a job where there was a high risk of encountering volatile substances. And this suggests a solution against the problem of volatile substance addiction, pointing out the importance of prohibiting children from working in workplaces where they might encounter inhalants. Substance addicts have high rates of attempting and committing suicide \[[@B11],[@B23]\]. Ögel et al. \[[@B19]\] found that 16.7% of inhalant abusers had suicide attempts in their history. In our study, this rate was similar: 16.1%.

There are a few fundamental characteristics which differentiate inhalant abusers from the abusers of other substances. Aggressiveness, committing substance-abuse related crimes, running away from home, harming oneself, and truancy, are more prevalent among these subjects than in adolescents who abuse other substances \[[@B24]-[@B29]\]. Concerning the effects of inhalants on the brains of addicts, cognitive problems are generally seen \[[@B30],[@B31]\]. Tolerance against inhalants develops fast and easily, and clinically-significant withdrawal symptoms do not occur \[[@B31]\]. To this list, when the adolescents living on the streets are added, there surfaces the need for questionnaire forms and scales to assess the addiction intensities of inhalant abusers \[[@B14]\]. Therefore, in 2005, Ögel et al. \[[@B32]\] developed YUKUD (Yeniden Inhalant Abuse Severity Scale). In that study, which was conducted with 50 volatile substance addict adolescents, the mean scale total score of the subjects was 61.4 ± 10.4. Similarly, in our study, the YUKUD scale was used to investigate the substance abuse intensity of the subjects. Obtained total scores varied between 10 and 50, and the average was 31.1 ± 9.7. No relationship was found between abuse intensity, and the age of onset of VSA, school attendance duration, or father\'s substance abuse. As the duration of living on the streets increases, the abuse intensity also increases, and these correlate almost at a statistically significant level. The YUKUD scores for those who had run away from home, had suicide attempts, had trouble with the law, and whose mothers were smoking cigarettes, were found to be higher, although not significantly so.

Coughing, shortness of breath, and wheezing are the most frequent complaints of inhalant abusers \[[@B6]\]. In a study conducted in the Philippines with 31 street children, the most frequently observed respiratory system complaints were listed as shortness of breath (38.7%), coughing (35.5%), and runny nose (29%) (33). Hellguist et al. \[[@B34]\], after analysing histopathologically the nasal biopsies taken from 10 painters who had occupational exposure to toluene and isobutyl acetate, reported that they encountered no normal mucosa. In a study conducted in Turkey, animals which were subjected to thinner inhalation had mucosal deformation, including inflammation and cilia loss in their nasal and larynx mucosa. In our study, the most frequently observed symptom was nasal congestion (45.2%). Following this came, in descending order of prevalence: sputum (38.7%), exercise intolerance (32.3%), coughing (22.6%), chest pain (16.1%), shortness of breath (9.7%), tachypnea (9.7%), wheezing (6.4%), sneezing (6.4%), and runny nose (6.4%).

In the literature, studies investigating the pulmonary functions of inhalant abusers are quite rare. Studies which investigate VSA-related morbidity and mortality are mostly limited to investigating the occupational exposure to solvents in industrial settings \[[@B8]\]. According to the U.S. Occupational Health and Safety Administration (OSHA), the safe limit allowable for solvents is 200 parts per million (ppm) for toluene, and 100 ppm for trichlorethylene. But, the concentration of toluene inhaled from a bag which contains Bally might reach 10,000 ppm \[[@B3],[@B8]\]. Schikler et al. \[[@B35]\], compared the pulmonary function tests of 42 inhalant addicts between the age of 11-31 years, and 20 healthy controls aged between 10-26 years, and found that the residual volumes of the addicts were significantly higher than those of the controls. Panacinar emphysema was observed in the lung tissues obtained from 3 subjects who were known as inhalant addicts and who had died because of trauma or accident, and this finding was proposed to explain the increase in residual volume \[[@B35]\].

In the literature, we found a single study addressing the relationship between VSA and respiratory functions. This study by Pogoy et al. \[[@B33]\] observed low FVC values indicating restrictive ventilatory pattern in 13 (41.9%) of the 31 street children between ages of 7-18 (mean age 14 ± 2) years, and with a mean duration of drug use of 2.6 ± 2.5 years. The FEV~1~values of all of their subjects were normal. In our study, the highest obtained FEV~1~and FVC values of the inhalant addicts were significantly lower than those of the control group (p \< 0.05). PEF and MEF~25-75~values of the study group were lower than in the control group, at a high level of statistical significance (p \< 0.01). FEV~1~/FVC ratio was not different between the groups (p \> 0.05). Calculating the percentage of reduction relative to the predicted values, 12 (41.4%) subjects in the study group were found to have low FVC values, indicating restrictive ventilatory pattern. FEV~1~of 2 subjects (6.89%) was reduced 20% or more. Restrictive ventilatory pattern was more prevalent in the study group, but not at a statistically significant level. Therefore, VSA might be causing decreases in lung volumes and flow velocities and, similar to the case of Pogoy et al.\'s study, this might be related to a restrictive ventilatory pattern. In our study, relations between a reduction of ≥ 20% in FVC and age of onset of VSA, duration of abuse, total amounts of abused inhalants, and respiratory system complaints were not statistically significant (p \> 0.05).

In the literature, we found no study evaluating the radiological findings of inhalant abusers. Dividing the study group into two subgroups according to their reduction in FVC, i.e. those who have vs. do not have restrictive ventilatory pattern, and then comparing their HRCT findings, small airways disease and the observed subpleural nodules rates we found no statistically significant differences between the two subgroups (p \> 0.05), while the rates of observed centrilobular nodules and atelectasis were significantly higher in the first subgroup (p \< 0.05). Restrictive ventilatory pattern was correlated with abnormal findings in HRCT, with a high level of statistical significance (p \< 0.01). In view of the findings observed in the lung scans of all of our inhalant addicted subjects, those who have a low FVC at spirometry should undergo HRCT.

In a study which compared the ventilation scintigraphies of 28 car painters who had occupational exposure to toluene, and 13 healthy controls, it was stated that Tc-99m diethylenetriaminepentaacetate (DTPA)\'s clearence from lungs was slower in car painters than in controls \[[@B36]\]. In another study, which was conducted with 10 painters and 10 healthy controls, occupational exposure/subjection to toluene was shown not to influence bronchoalveolar epithelial permeability. In our study, we performed ventilation scintigraphy in 21 volatile substance addicts, and 3 (14.2%) of the subjects were found to have hypoventilation in the right apical region, while 1 (4.7%) had retention in central airways. No relationship was found between a reduction in FVC, and perfusion and ventilation disorders.

Inhalation of volatile substances for their psycho active properties has a very long history and has been widely detected all around the world in different age groups, including very young people. As volatile substance abuse is a social problem, it requires a social response. VSA will best be addressed by addressing the social problems facing young people. Respiratory complications of volatile substances are well noted to clinicians as a clinical observation, but have not been documented or studied adequately in clinical research. This study has shown a positive correlation between volatile substance abuse and the development of restrictive ventilatory pattern. But further evaluation of long-term effects (more than 10 years) of volatile substances, and more comprehensive studies are needed to enable more precise conclusions to be drawn.
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